Antimicrobial proteins may be both mediators and 'end-effectors' in this cytokine-regulated commitment to inflammation and proliferation, as indicated by the paradigm of the crosstalk between ...
Unexpectedly, rapamycin-mediated inhibition of mTOR caused an increase in the production of pro-inflammatory cytokines, such as IL-12, IL-23 and IL-6, and a decrease in the production of the anti ...
Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.
Methods: The effects of different doses of A77 1726 on intracytoplasmic expression and extracellular concentration of inflammatory cytokines (tumour necrosis factor α (TNFα), interleukin (IL) 1β, IL6) ...